Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae

Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae After Traumatic Brain Injury

The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived mononuclear cell transplantation in the management of neurological sequelae after traumatic brain injury

To evaluate the safety and efficacy of autologous bone marrow-derived mononuclear cell transplantation in 25 patients with neurological sequelae after traumatic brain injury compared with 25 patients in control group (no intervention) at the time points of baseline, 3rd month (D90), 6th month (D180), and 12th month (D360).

Inclusion Criteria:

• Age: from 20 to 50 years
• Gender: either sex
• Duration after Brain trauma: 6 - 12 months
• Functional Independence Measure - FIM < 69
• Closed head injury

Exclusion Criteria:

• Neurologic impairment or neurological disease before the time of the accident.
• Active infections
• Tumours or failure of heart, lung, liver or kidney, respiratory distress syndrome
• Anaemia, clotting disorder
• Cancer
• Pregnancy
• Alcoholic
• Patient was unemployed or did not attend school before the accident.
• Severe injuries: spinal cord injury, pelvic inflammation, cardiopulmonary